Sebastien J Hotte1, Antonio Finelli2, Kim N Chi3, Christina Canil4, Neil Fleshner2, Anil Kapoor, Michael Kolinsky5, Shawn Malone4, Christopher Morash4, Tamim Niazi6, Krista L Noonan3, Michael Ong4, Frederic Pouliot7, Bobby Shayegan8, Alan I So9, Delna Sorabji10, Huong Hew10, Laura Park-Wyllie10, Fred Saad11. 1. Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada. 2. Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada. 3. BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada. 4. The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada. 5. Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada. 6. Jewish General Hospital, McGill University, Montreal, QC, Canada. 7. Centre hospitalier universitaire de Québec, Université Laval, Quebec City, QC, Canada. 8. St. Joseph's Healthcare, McMaster University, Hamilton, ON, Canada. 9. Prostate Centre at Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada. 10. Medical Affairs, Janssen Inc, Toronto, ON, Canada. 11. Centre hospitalier de l'Université de Montréal, Montreal, QC, Canada.
Abstract
INTRODUCTION: The Canadian Genitourinary Research Consortium (GURC) conducted a consensus development conference leading to 31 recommendations. Using the GURC consensus development questionnaire, we conducted a survey to measure the corresponding community-based practices on the management of metastatic castration-sensitive prostate cancer (mCSPC), metastatic castration-resistant prostate cancer (mCRPC) and non-metastatic castration-resistant prostate cancer (nmCRPC). METHODS: An 87-item online questionnaire was sent to 600 community urologists and oncologists involved in the treatment of prostate cancer. RESULTS: Seventy-two community physicians responded to the survey. Of note, 50% community physicians indicated they would treat nmCRPC with agents approved for this indication if advanced imaging showed metastases. Radiation to the prostate for low-volume mCSPC was identified as a treatment practice by 27% of community physicians, and 35% indicated docetaxel as the next line of treatment after use of apalutamide. Use of genetic testing was reported in 36% of community physicians for newly diagnosed metastatic prostate cancer. CONCLUSIONS: There are several areas of community-based management of advanced prostate cancer that could represent potential areas for education, practice tools, and future research.
INTRODUCTION: The Canadian Genitourinary Research Consortium (GURC) conducted a consensus development conference leading to 31 recommendations. Using the GURC consensus development questionnaire, we conducted a survey to measure the corresponding community-based practices on the management of metastatic castration-sensitive prostate cancer (mCSPC), metastatic castration-resistant prostate cancer (mCRPC) and non-metastatic castration-resistant prostate cancer (nmCRPC). METHODS: An 87-item online questionnaire was sent to 600 community urologists and oncologists involved in the treatment of prostate cancer. RESULTS: Seventy-two community physicians responded to the survey. Of note, 50% community physicians indicated they would treat nmCRPC with agents approved for this indication if advanced imaging showed metastases. Radiation to the prostate for low-volume mCSPC was identified as a treatment practice by 27% of community physicians, and 35% indicated docetaxel as the next line of treatment after use of apalutamide. Use of genetic testing was reported in 36% of community physicians for newly diagnosed metastatic prostate cancer. CONCLUSIONS: There are several areas of community-based management of advanced prostate cancer that could represent potential areas for education, practice tools, and future research.
Authors: Silke Gillessen; Gerhardt Attard; Tomasz M Beer; Himisha Beltran; Alberto Bossi; Rob Bristow; Brett Carver; Daniel Castellano; Byung Ha Chung; Noel Clarke; Gedske Daugaard; Ian D Davis; Johann de Bono; Rodolfo Borges Dos Reis; Charles G Drake; Ros Eeles; Eleni Efstathiou; Christopher P Evans; Stefano Fanti; Felix Feng; Karim Fizazi; Mark Frydenberg; Martin Gleave; Susan Halabi; Axel Heidenreich; Celestia S Higano; Nicolas James; Philip Kantoff; Pirkko-Liisa Kellokumpu-Lehtinen; Raja B Khauli; Gero Kramer; Chris Logothetis; Fernando Maluf; Alicia K Morgans; Michael J Morris; Nicolas Mottet; Vedang Murthy; William Oh; Piet Ost; Anwar R Padhani; Chris Parker; Colin C Pritchard; Mack Roach; Mark A Rubin; Charles Ryan; Fred Saad; Oliver Sartor; Howard Scher; Avishay Sella; Neal Shore; Matthew Smith; Howard Soule; Cora N Sternberg; Hiroyoshi Suzuki; Christopher Sweeney; Matthew R Sydes; Ian Tannock; Bertrand Tombal; Riccardo Valdagni; Thomas Wiegel; Aurelius Omlin Journal: Eur Urol Date: 2017-06-24 Impact factor: 20.096
Authors: Fred Saad; Christina Canil; Antonio Finelli; Sebastien J Hotte; Shawn Malone; Bobby Shayegan; Alan I So; Lorne Aaron; Naveen S Basappa; Henry J Conter; Brita Danielson; Geoffrey Gotto; Robert J Hamilton; Jason P Izard; Anil Kapoor; Michael Kolinsky; Aly-Khan A Lalani; Jean-Baptiste Lattouf; Christopher Morash; Scott C Morgan; Tamim Niazi; Krista L Noonan; Michael Ong; Ricardo A Rendon; Sandeep Sehdev; Huong Hew; Laura Park-Wyllie; Kim N Chi Journal: Can Urol Assoc J Date: 2019-11-05 Impact factor: 1.862
Authors: Ivan R Diamond; Robert C Grant; Brian M Feldman; Paul B Pencharz; Simon C Ling; Aideen M Moore; Paul W Wales Journal: J Clin Epidemiol Date: 2014-04 Impact factor: 6.437
Authors: Christopher C Parker; Nicholas D James; Christopher D Brawley; Noel W Clarke; Alex P Hoyle; Adnan Ali; Alastair W S Ritchie; Gerhardt Attard; Simon Chowdhury; William Cross; David P Dearnaley; Silke Gillessen; Clare Gilson; Robert J Jones; Ruth E Langley; Zafar I Malik; Malcolm D Mason; David Matheson; Robin Millman; J Martin Russell; George N Thalmann; Claire L Amos; Roberto Alonzi; Amit Bahl; Alison Birtle; Omar Din; Hassan Douis; Chinnamani Eswar; Joanna Gale; Melissa R Gannon; Sai Jonnada; Sara Khaksar; Jason F Lester; Joe M O'Sullivan; Omi A Parikh; Ian D Pedley; Delia M Pudney; Denise J Sheehan; Narayanan Nair Srihari; Anna T H Tran; Mahesh K B Parmar; Matthew R Sydes Journal: Lancet Date: 2018-10-21 Impact factor: 79.321
Authors: Roderick Clark; Miran Kenk; Kristen McAlpine; Emily Thain; Kirsten M Farncombe; Colin C Pritchard; Robert Nussbaum; Alexander W Wyatt; Johann de Bono; Danny Vesprini; Yvonne Bombard; Justin Lorentz; Steven Narod; Raymond Kim; Neil Fleshner Journal: Can Urol Assoc J Date: 2021-12 Impact factor: 1.862